









Arvinas up after early-stage trial shows drug lowers key Parkinson's marker

ReutersMar 18, 2026 11:18 AM

Shares of biotech firm Arvinas ARVN.O rise 2% to $12.22 premarket

Co says its experimental drug ARV-102 reduced markers linked to Parkinson's - a progressive brain disorder affecting movement, memory and sleep - in a small, early-stage trial

Adds the once-daily pill cut levels of LRRK2, a protein that builds up in Parkinson's patients' spinal fluid, by about half in 28 days

Says the trial also showed reductions in markers associated with inflammation and cell damage, linked to Parkinson's disease and the rare, rapidly progressive brain disorder PSP

Adds no serious side effects were reported and all adverse events were mild

Co plans to start a new trial for PSP in the second quarter of 2026, pending regulatory feedback

ARVN shares up 1.26% YTD vs. a ~38% decline in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

SpaceX IPO Seeks to Raise Over 50 Billion: Will This Largest-Ever Capital Flow Be Injected Into Bitcoin?

SpaceX may increase its Bitcoin holdings following an IPO to support the development of the Grok model and spatial AI data centers.

Should You Buy Upcoming SpaceX Now or Tesla After a 20% Pullback?

TradingKey - Media reports indicate that SpaceX, founded by Tesla (TSLA.US) CEO Elon Musk, plans to file its IPO prospectus with regulators later this week or next week. The company aims to raise more than $75 billion in the IPO, exceeding the previously reported $50 billion. Its latest valuation is

USDC Architect Circle Plummets 20% as U.S. Lawmakers Target Stablecoin Interest

Regulatory headwinds triggered a plunge of more than 20% in Circle’s share price, yet ARK Invest bucked the trend by purchasing over $20 million.

Pop Mart Revenue Tops 30 Billion Net Profit Surges 284%, Why Did Stock Price Plummet 15%?

TradingKey - On March 25, following the release of Pop Mart's (09992.HK) 2025 annual results, its Hong Kong-listed shares plummeted by as much as 15% intraday. Although the full-year performance was robust and generally aligned with market expectations, investor dissatisfaction was directly reflected in the stock price.

SpaceX IPO Approaches: Behind the $75 Billion Fundraising Rumors, What Is the Capital Market Betting On?

TradingKey - U.S. tech media outlet The Information reports that SpaceX plans to file an IPO prospectus with regulators as early as this week or next. Advisors expect the offering could raise more than $75 billion.

Tradingkey

KeyAI

